论文部分内容阅读
目的:评价托伐普坦对肝硬化失代偿期患者稀释性低钠血症的临床疗效。方法:选取2013年6月—2014年12月间收治的肝硬化失代偿期稀释性低钠血症患者76例,将其随机分成对照组和治疗组,每组38例;对照组患者均给予常规治疗,观察组患者在对照组治疗的基础上加用托伐普坦治疗,比较两组患者治疗4 d和7 d后的血Na+浓度正常率,以及治疗后24 h内的总排尿量情况。结果:治疗组患者治疗4 d和7 d后的血Na+浓度正常率分别为60.53%和65.79%,明显高于对照组为21.05%和26.32%(P<0.05);治疗组患者在治疗后24 h内总尿量大于3 500 m L的百分率明显高于对照组(P<0.05)。结论:托伐普坦与常规治疗肝硬化失代偿期稀释性低钠血症患者治疗4 d和7 d后的血Na+浓度正常率高于常规治疗,且患者在治疗后24 h内总尿量明显增多。
Objective: To evaluate the clinical efficacy of tolvaptan in patients with decompensated cirrhosis and hyponatremia. Methods: A total of 76 patients with decompensated cirrhosis and hyponatremia admitted from June 2013 to December 2014 were randomly divided into control group and treatment group, with 38 patients in each group. Patients in control group Patients in the observation group were treated with tolvaptan on the basis of the control group. The normal rate of blood Na + concentration after 4 and 7 days of treatment in both groups were compared, and the total urinary volume within 24 hours after treatment Happening. Results: The normal rates of blood Na + concentration in treatment group were 60.53% and 65.79% on the 4th and 7th day respectively, which were significantly higher than those in the control group (21.05% and 26.32%, P <0.05) h, the total urine output was greater than 3 500 m L percentage was significantly higher than the control group (P <0.05). CONCLUSION: Both tolvaptan and normal sodium in patients with decompensated cirrhosis and hyponatremia after 4 and 7 days of treatment have a higher normal rate of blood Na + concentration than that of conventional treatment, and the total urine in 24 hours after treatment Significantly increased.